You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 264 No. 21, December 5, 1990 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Primary Hypertriglyceridemia With Borderline High Cholesterol and Elevated Apolipoprotein B Concentrations

Comparison of Gemfibrozil vs Lovastatin Therapy

Gloria Lena Vega, PhD; Scott M. Grundy, MD, PhD

JAMA. 1990;264(21):2759-2763.


Abstract

A common pattern of dyslipidemia is elevated levels of plasma triglyceride, borderline high total cholesterol, reduced high-density lipoprotein, and increased apolipoprotein B. This pattern of dyslipidemia frequently is associated with premature coronary heart disease. Nicotinic acid is the drug of first choice for this pattern. In this study, gemfibrozil and lovastatin were compared for their effects on the overall lipoprotein profile in 13 men with this type of dyslipidemia. Both drugs significantly reduced very-low—density lipoprotein and intermediate-density lipoprotein cholesterol levels, and both modestly raised high-density lipoprotein cholesterol levels. Gemfibrozil therapy, however, failed to reduce total cholesterol or total apolipoprotein B levels, whereas lovastatin therapy lowered levels of total cholesterol by 28%, low-density lipoprotein cholesterol by 33%, and total apolipoprotein B by 32%. Moreover, lovastatin therapy caused greater declines in lipoprotein cholesterol ratios than gemfibrozil therapy. Lovastatin thus seems to have certain advantages over gemfibrozil for treatment of elevated plasma triglyceride levels accompanied by borderline high total cholesterol and raised apolipoprotein B levels; therefore, lovastatin therapy should be considered as one approach for management of this condition.

(JAMA. 1990;264:2759-2763)



Author Affiliations

From the Center for Human Nutrition (Drs Vega and Grundy), the Departments of Clinical Nutrition (Drs Vega and Grundy), Internal Medicine (Dr Grundy), and Biochemistry (Dr Grundy), University of Texas Southwestern Medical Center at Dallas and Veterans Affairs Medical Center, Dallas (Dr Grundy).


Footnotes

Reprint requests to Center for Human Nutrition, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235-9052 (Dr Grundy).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney
Arch Intern Med 2004;164:697-705.
ABSTRACT | FULL TEXT  

ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina)
Gibbons et al.
Circulation 2003;107:149-158.
FULL TEXT  

ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina)
Committee Members et al.
J Am Coll Cardiol 2003;41:159-168.
FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Can Measurement of Apolipoprotein B Replace the Lipid Profile in the Follow-up of Patients with Lipoprotein Disorders?
Durrington
Clin. Chem. 2002;48:401-402.
FULL TEXT  

Counterpoint To (measure apo)B or not to (measure apo)B: a critique of modern medical decision-making
Sniderman
Clin. Chem. 1997;43:1310-1314.
ABSTRACT | FULL TEXT  

Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia
Planella et al.
Clin. Chem. 1997;43:808-815.
ABSTRACT | FULL TEXT  

Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients With Primary Type Ha or IIb Hyperlipidemia
Farnier et al.
Arch Intern Med 1994;154:441-449.
ABSTRACT  

Comparison of Gemfibrozil and Lovastatin in Patients With High Low-Density Lipoprotein and Low High-Density Lipoprotein Cholesterol Levels
McKenney et al.
Arch Intern Med 1992;152:1781-1787.
ABSTRACT  

Two Different Views of the Relationship of Hypertriglyceridemia to Coronary Heart Disease: Implications for Treatment
Grundy and Vega
Arch Intern Med 1992;152:28-34.
ABSTRACT  

LOVASTATIN VS. GEMFIBROZIL FOR DYSLIPIDEMIA
JWatch General 1990;1990:3-3.
FULL TEXT  

Treatment Choices for Hypertriglyceridemia
Connor
JAMA 1990;264:2797-2798.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.